PARP抑制剂与免疫检查点抑制剂联合治疗在妇科恶性肿瘤中的应用
PARP Inhibitors Combined with Immune Checkpoint Inhibitors in the Treatment of Gynecological Malignant Tumors
周琳 1袁琳 1万一聪 1张林 1程文俊 1姜旖1
作者信息
- 1. 210029 南京医科大学第一附属医院妇科
- 折叠
摘要
近年来肿瘤靶向和免疫治疗的研究进展迅速,如多腺苷二磷酸核糖聚合酶抑制剂[poly(ADP-ribose)polymerase inhibitor,PARPi]、免疫检查点抑制剂(immune checkpoint inhibitors,ICI)等已改变了妇科肿瘤的传统治疗模式,但部分患者疗效有限或出现耐药.临床前研究发现,PARPi损伤DNA修复过程,可造成肿瘤突变负荷与肿瘤特异性抗原增加,调节肿瘤微环境,刺激肿瘤浸润淋巴细胞(tumor infiltrating lymphocytes,TIL)产生并促进抗肿瘤免疫反应,为PARPi与ICI联合治疗提供了理论基础.近年多项临床研究发现PARPi与ICI联合使用可显著改善妇科恶性肿瘤患者的预后.
Abstract
In recent years the progress of targeted therapy and immunotherapy has developed rapidly,such as poly(ADP-ribose)polymerase inhibitor(PARPi)and immune checkpoint inhibitors(ICI)have changed the traditional treatment pattern of gynecologic tumors,but some patients have limited efficacy or develop drug resistance.Preclinical studies have found that PARPi damages DNA repair process,results in increasing tumor mutation burden and tumor-specific antigen neoantigens,modulates the tumor microenvironment,and stimulates the production of tumor infiltrating lymphocytes(TIL)and promotes anti-tumor immune response,which providing a theoretical basis for the combination treatment of PARPi and ICI.Recently,many clinical studies have found that the combination of PARPi and ICI can significantly improve the prognosis of patients with gynecological malignant tumors.
关键词
生殖器肿瘤,女(雌)性/卵巢肿瘤/子宫内膜肿瘤/多(ADP核糖)聚合酶抑制剂/免疫检查点抑制剂/治疗Key words
Genital neoplasms,female/Ovarian neoplasms/Endometrial neoplasms/Poly(ADP-ribose)polymerase inhibitors/Immune checkpoint inhibitors/Therapy引用本文复制引用
基金项目
国家自然科学基金(82373387)
国家自然科学基金(82103286)
江苏省卫健委老年健康研究项目(LKM2022032)
出版年
2024
国家科技期刊平台
NSTL
万方数据